{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T02:28:47Z","timestamp":1773541727484,"version":"3.50.1"},"reference-count":93,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T00:00:00Z","timestamp":1582761600000},"content-version":"am","delay-in-days":391,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gyn\u00e9cologie Obst\u00e9trique Fertilit\u00e9 &amp; S\u00e9nologie\u00a0"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.gofs.2018.12.013","type":"journal-article","created":{"date-parts":[[2019,2,5]],"date-time":"2019-02-05T01:32:51Z","timestamp":1549330371000},"page":"134-154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pertinence des marqueurs tumoraux, scores (cliniques et biologiques) et algorithmes \u00e0 vis\u00e9e diagnostique et pronostique devant une masse ovarienne suspecte d\u2019un cancer \u00e9pith\u00e9lial. Article r\u00e9dig\u00e9 sur la base de la recommandation nationale de bonnes pratiques cliniques en canc\u00e9rologie intitul\u00e9e \u00ab\u00a0Conduites \u00e0 tenir initiales devant des patientes atteintes d\u2019un cancer \u00e9pith\u00e9lial de l\u2019ovaire\u00a0\u00bb \u00e9labor\u00e9e par FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY sous l\u2019\u00e9gide du CNGOF et labellis\u00e9e par l\u2019INCa"],"prefix":"10.1016","volume":"47","author":[{"given":"S.","family":"Bendifallah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Body","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Dara\u00ef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9465-0335","authenticated-orcid":false,"given":"L.","family":"Ouldamer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gofs.2018.12.013_bib0470","first-page":"6143","article-title":"Characterization of the CA 125\u00a0antigen associated with human epithelial ovarian carcinomas","volume":"46","author":"Davis","year":"1986","journal-title":"Cancer Res"},{"key":"10.1016\/j.gofs.2018.12.013_bib0475","first-page":"11","article-title":"[Ca-125\u00a0in diagnosis and monitoring of patients with ovarian cancer]","volume":"54","author":"Bocheva","year":"2015","journal-title":"Akush Ginekol (Sofiia)"},{"key":"10.1016\/j.gofs.2018.12.013_bib0480","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/bjc.2011.593","article-title":"CA-125\u00a0can be part of the tumour evaluation criteria in ovarian cancer trials\u00a0: experience of the GCIG CALYPSO trial","volume":"106","author":"Alexandre","year":"2012","journal-title":"Br J Cancer"},{"issue":"Suppl.\u00a03","key":"10.1016\/j.gofs.2018.12.013_bib0485","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1136\/ijgc-00009577-200511001-00015","article-title":"New tumor markers: CA125\u00a0and beyond","volume":"15","author":"Bast","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.gofs.2018.12.013_bib0490","doi-asserted-by":"crossref","first-page":"276","DOI":"10.21037\/atm.2017.05.13","article-title":"Circulating biomarkers in epithelial ovarian cancer diagnosis: from present to future perspective","volume":"5","author":"Montagnana","year":"2017","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.gofs.2018.12.013_bib0495","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1097\/IGC.0000000000000804","article-title":"Diagnostic performance of risk of ovarian malignancy algorithm against CA125\u00a0and HE4\u00a0in connection with ovarian cancer: a meta-analysis","volume":"26","author":"Dayyani","year":"2016","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.gofs.2018.12.013_bib0500","doi-asserted-by":"crossref","first-page":"6127","DOI":"10.1007\/s13277-014-1811-6","article-title":"Diagnostic accuracy of serum HE4, CA125\u00a0and ROMA in patients with ovarian cancer: a meta-analysis","volume":"35","author":"Wang","year":"2014","journal-title":"Tumour Biol J"},{"key":"10.1016\/j.gofs.2018.12.013_bib0505","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3892\/mco.2014.279","article-title":"Comparison of serum human epididymis protein 4\u00a0and carbohydrate antigen 125\u00a0as markers in ovarian cancer: a meta-analysis","volume":"2","author":"Zhen","year":"2014","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.gofs.2018.12.013_bib0510","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1136\/jclinpath-2012-201031","article-title":"Serum human epididymis protein 4\u00a0vs carbohydrate antigen 125\u00a0for ovarian cancer diagnosis: a systematic review","volume":"66","author":"Ferraro","year":"2013","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.gofs.2018.12.013_bib0515","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ejogrb.2012.10.036","article-title":"Human epididymis protein 4\u00a0for differential diagnosis between benign gynecologic disease and ovarian cancer: a systematic review and meta-analysis","volume":"167","author":"Lin","year":"2013","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.gofs.2018.12.013_bib0520","doi-asserted-by":"crossref","first-page":"5427","DOI":"10.7314\/APJCP.2012.13.11.5427","article-title":"Diagnostic value of human epididymis protein 4\u00a0compared with mesothelin for ovarian cancer: a systematic review and meta-analysis","volume":"13","author":"Lin","year":"2012","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.gofs.2018.12.013_bib0525","article-title":"Clinical performance of LOCI\u2122-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9\u00a0and AFP in gynecological cancers","volume":"39","author":"Dolscheid-Pommerich","year":"2017","journal-title":"Tumour Biol J"},{"key":"10.1016\/j.gofs.2018.12.013_bib0530","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.5301\/jbm.5000139","article-title":"CA 19-9\u00a0in evaluation of adnexal mass: retrospective cohort analysis and review of the literature","volume":"30","author":"Sagi-Dain","year":"2015","journal-title":"Int J Biol Markers"},{"key":"10.1016\/j.gofs.2018.12.013_bib0535","doi-asserted-by":"crossref","first-page":"49565","DOI":"10.18632\/oncotarget.10391","article-title":"Clinical significance and diagnostic value of serum CEA, CA19-9\u00a0and CA72-4\u00a0in patients with gastric cancer","volume":"7","author":"Liang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.gofs.2018.12.013_bib0540","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/bjc.1985.161","article-title":"CA19-9\u00a0as a marker for ovarian cancer: alone and in comparison with CA125","volume":"52","author":"Canney","year":"1985","journal-title":"Br J Cancer"},{"key":"10.1016\/j.gofs.2018.12.013_bib0545","first-page":"217","article-title":"Clinical usefulness of sialyl SSEA-1\u00a0antigen as tumor marker for ovarian cancer as compared with CA125, CA19-9, TPA, IAP, CEA and ferritin","volume":"41","author":"Yabushita","year":"1989","journal-title":"Nihon Sanka Fujinka Gakkai Zasshi"},{"key":"10.1016\/j.gofs.2018.12.013_bib0550","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0090-8258(92)90031-D","article-title":"The concomitant determination of different serum tumor markers in epithelial ovarian cancer: relevance for monitoring the response to chemotherapy and follow-up of patients","volume":"44","author":"Fioretti","year":"1992","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.gofs.2018.12.013_bib0555","doi-asserted-by":"crossref","first-page":"9660","DOI":"10.18632\/oncotarget.14173","article-title":"Diagnostic accuracy of urine HE4\u00a0in patients with ovarian cancer: a meta-analysis","volume":"8","author":"Jia","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.gofs.2018.12.013_bib0560","doi-asserted-by":"crossref","first-page":"e0155495","DOI":"10.1371\/journal.pone.0155495","article-title":"Circulating cell free DNA as the diagnostic marker for ovarian cancer: a systematic review and meta-analysis","volume":"11","author":"Zhou","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.gofs.2018.12.013_bib0565","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.ygyno.2017.07.138","article-title":"Systematic review: tumor-associated antigen autoantibodies and ovarian cancer early detection","volume":"147","author":"Fortner","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.gofs.2018.12.013_bib0570","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1158\/1055-9965.EPI-13-0621","article-title":"Serologic autoantibodies as diagnostic cancer biomarkers\u00a0\u2014\u00a0a review","volume":"22","author":"Zaenker","year":"2013","journal-title":"Cancer Epidemiol Biomark"},{"issue":"3","key":"10.1016\/j.gofs.2018.12.013_bib0575","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/ijc.31335","article-title":"Tumor-associated autoantibodies as early detection markers for ovarian cancer? A prospective evaluation","volume":"143","author":"Kaaks","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1016\/j.gofs.2018.12.013_bib0580","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ygyno.2008.08.031","article-title":"A novel multiple marker bioassay utilizing HE4\u00a0and CA125\u00a0for the prediction of ovarian cancer in patients with a pelvic mass","volume":"112","author":"Moore","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.gofs.2018.12.013_bib0585","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/sj.bjc.6606092","article-title":"HE4\u00a0and CA125\u00a0as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm","volume":"104","author":"Van Gorp","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.gofs.2018.12.013_bib0590","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ygyno.2012.09.034","article-title":"The use of HE4\u00a0in the prediction of ovarian cancer in Asian women with a pelvic mass","volume":"128","author":"Chan","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.gofs.2018.12.013_bib0595","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.ygyno.2015.06.021","article-title":"A novel diagnostic index combining HE4, CA125\u00a0and age may improve triage of women with suspected ovarian cancer\u00a0\u2014\u00a0An international multicenter study in women with an ovarian mass","volume":"138","author":"Karlsen","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.gofs.2018.12.013_bib0600","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1080\/00365513.2016.1208452","article-title":"Approaches to the detection of ovarian cancer","volume":"245","author":"H\u00f8gdall","year":"2016","journal-title":"Scand J Clin"},{"key":"10.1016\/j.gofs.2018.12.013_bib0605","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ygyno.2016.01.023","article-title":"Comparing the Copenhagen Index (CPH-I) and Risk of Ovarian Malignancy Algorithm (ROMA): two equivalent ways to differentiate malignant from benign ovarian tumors before surgery?","volume":"140","author":"Yoshida","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.gofs.2018.12.013_bib0610","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/ijgo.12371","article-title":"Comparison of the Copenhagen Index versus ROMA for the preoperative assessment of women with ovarian tumors","volume":"140","author":"Minar","year":"2018","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.gofs.2018.12.013_bib0615","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ygyno.2016.03.019","article-title":"Rajavithi-ovarian cancer predictive score (R-OPS): a new scoring system for predicting ovarian malignancy in women presenting with a pelvic mass","volume":"141","author":"Yanaranop","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.gofs.2018.12.013_bib0620","doi-asserted-by":"crossref","first-page":"82e1","DOI":"10.1016\/j.ajog.2016.03.003","article-title":"Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses","volume":"215","author":"Coleman","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.gofs.2018.12.013_bib0625","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/jso.21398","article-title":"Preoperative serum CA-125\u00a0levels and risk of suboptimal cytoreduction in ovarian cancer: a meta-analysis","volume":"101","author":"Kang","year":"2010","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.gofs.2018.12.013_bib0630","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ygyno.2008.09.020","article-title":"Can the preoperative Ca-125\u00a0level predict optimal cytoreduction in patients with advanced ovarian carcinoma? A single institution cohort study","volume":"112","author":"Vorgias","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.gofs.2018.12.013_bib0635","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.ejso.2005.05.009","article-title":"A multicenter study of CA 125\u00a0level as a predictor of non-optimal primary cytoreduction of advanced epithelial ovarian cancer","volume":"31","author":"Gemer","year":"2005","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.gofs.2018.12.013_bib0640","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s00432-011-0977-1","article-title":"Prognostic and predictive relevance of CA-125\u00a0at primary surgery of ovarian cancer","volume":"137","author":"Mury","year":"2011","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.gofs.2018.12.013_bib0645","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/ijgc-00009577-200603000-00006","article-title":"The utility of presurgical CA125\u00a0to predict optimal tumor cytoreduction of epithelial ovarian cancer","volume":"16","author":"Barlow","year":"2006","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.gofs.2018.12.013_bib0650","first-page":"59","article-title":"Preoperative CA 125\u00a0levels: an independent prognostic factor for epithelial ovarian cancer","volume":"100","author":"Cooper","year":"2002","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.gofs.2018.12.013_bib0655","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1136\/ijgc-00009577-200807000-00004","article-title":"Preoperative serum CA125\u00a0levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer","volume":"18","author":"Arits","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.gofs.2018.12.013_bib0660","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1006\/gyno.2000.5749","article-title":"The ability of preoperative serum CA-125\u00a0to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma","volume":"77","author":"Chi","year":"2000","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.gofs.2018.12.013_bib0665","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1136\/ijgc-00009577-200303000-00003","article-title":"CA125\u00a0levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer","volume":"13","author":"Memarzadeh","year":"2003","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.gofs.2018.12.013_bib0670","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1048-891x.2004.14065.x","article-title":"Preoperative predictors of suboptimal primary surgical cytoreduction in women with clinical evidence of advanced primary epithelial ovarian cancer","volume":"14","author":"Brockbank","year":"2004","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.gofs.2018.12.013_bib0675","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1006\/gyno.2002.6719","article-title":"Can serum CA-125\u00a0levels predict the optimal primary cytoreduction in patients with advanced ovarian carcinoma?","volume":"86","author":"Saygili","year":"2002","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.gofs.2018.12.013_bib0680","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ijgo.2003.10.006","article-title":"CA-125\u00a0levels in predicting optimal cytoreductive surgery in patients with advanced epithelial ovarian carcinoma","volume":"84","author":"Alc\u00e1zar","year":"2004","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.gofs.2018.12.013_bib0685","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000076236","article-title":"Can optimal primary cytoreduction be predicted in advanced stage epithelial ovarian cancer? Role of preoperative serum CA-125\u00a0level","volume":"57","author":"Obeidat","year":"2004","journal-title":"Gynecol Obstet Invest"},{"key":"10.1016\/j.gofs.2018.12.013_bib0690","first-page":"29","article-title":"Usefulness of human epididymis protein 4\u00a0in predicting optimal cytoreductive therapy in patients with advanced ovarian cancer","volume":"22","author":"Paunovic","year":"2017","journal-title":"J BUON"},{"key":"10.1016\/j.gofs.2018.12.013_bib0695","doi-asserted-by":"crossref","first-page":"14765","DOI":"10.1007\/s13277-016-5335-0","article-title":"Serum HE4\u00a0superior to CA125\u00a0in predicting poorer surgical outcome of epithelial ovarian cancer","volume":"37","author":"Shen","year":"2016","journal-title":"Tumour Biol J"},{"key":"10.1016\/j.gofs.2018.12.013_bib0700","first-page":"309","article-title":"Usefulness of human epididymis protein 4\u00a0in predicting cytoreductive surgical outcomes for advanced ovarian tubal and peritoneal carcinoma","volume":"27","author":"Tang","year":"2015","journal-title":"Chin J Cancer Res"},{"key":"10.1016\/j.gofs.2018.12.013_bib0705","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1757-2215-7-62","article-title":"Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer","volume":"7","author":"Chudecka-G\u0142az","year":"2014","journal-title":"J Ovarian Res"},{"key":"10.1016\/j.gofs.2018.12.013_bib0710","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ygyno.2012.11.040","article-title":"Can the preoperative HE4\u00a0level predict optimal cytoreduction in patients with advanced ovarian carcinoma?","volume":"128","author":"Angioli","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.gofs.2018.12.013_bib0715","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ygyno.2012.11.023","article-title":"Preoperative HE4\u00a0expression in plasma predicts surgical outcome in primary ovarian cancer patients: results from the OVCAD study","volume":"128","author":"Braicu","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.gofs.2018.12.013_bib0720","first-page":"6879","article-title":"Modeling CA-125\u00a0during neoadjuvant chemotherapy for predicting optimal cytoreduction and relapse risk in ovarian cancer","volume":"37","author":"Ducoulombier","year":"2017","journal-title":"Anticancer Res"},{"key":"10.1016\/j.gofs.2018.12.013_bib0725","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1272\/jnms.84.170","article-title":"Serum CA 125\u00a0level after neoadjuvant chemotherapy is predictive of prognosis and debulking surgery outcomes in advanced epithelial ovarian cancer","volume":"84","author":"Matsuhashi","year":"2017","journal-title":"J Nippon Med Sch"},{"key":"10.1016\/j.gofs.2018.12.013_bib0730","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1007\/s13277-012-0471-7","article-title":"Does HE4\u00a0have a role as biomarker in the recurrence of ovarian cancer?","volume":"33","author":"Plotti","year":"2012","journal-title":"Tumour Biol J"},{"key":"10.1016\/j.gofs.2018.12.013_bib0735","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ygyno.2016.11.021","article-title":"Optimizing the treatment of ovarian cancer: neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection","volume":"144","author":"Gill","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.gofs.2018.12.013_bib0740","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13048-016-0270-7","article-title":"Serum CA125\u00a0and HE4\u00a0levels as predictors for optimal interval surgery and platinum sensitivity after neoadjuvant platinum-based chemotherapy in patients with advanced epithelial ovarian cancer","volume":"9","author":"Pelissier","year":"2016","journal-title":"J Ovarian Res"},{"key":"10.1016\/j.gofs.2018.12.013_bib0745","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.7150\/jca.16761","article-title":"Reduction of CA125\u00a0levels during neoadjuvant chemotherapy can predict cytoreduction to no visible residual disease in patients with advanced epithelial ovarian cancer, primary carcinoma of fallopian tube and peritoneal carcinoma","volume":"7","author":"Zeng","year":"2016","journal-title":"J Cancer"},{"key":"10.1016\/j.gofs.2018.12.013_bib0750","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1097\/IGC.0000000000000434","article-title":"The impact of percent reduction in CA-125\u00a0levels on prediction of the extent of interval cytoreduction and outcome in patients with advanced-stage cancer of m\u00fcllerian origin treated with neoadjuvant chemotherapy","volume":"25","author":"Mahdi","year":"2015","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.gofs.2018.12.013_bib0755","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3802\/jgo.2013.24.2.141","article-title":"CA-125\u00a0cut-off value as a predictor for complete interval debulking surgery after neoadjuvant chemotherapy in patients with advanced ovarian cancer","volume":"24","author":"Furukawa","year":"2013","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.gofs.2018.12.013_bib0760","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ygyno.2012.02.006","article-title":"Changes in serum CA-125\u00a0can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy","volume":"125","author":"Rodriguez","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.gofs.2018.12.013_bib0765","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ygyno.2006.07.004","article-title":"\u201cOptimal\u201d cytoreduction for advanced epithelial ovarian cancer: a commentary","volume":"103","author":"Eisenkop","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.gofs.2018.12.013_bib0770","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ygyno.2006.03.051","article-title":"What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?","volume":"103","author":"Chi","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.gofs.2018.12.013_bib0775","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.ygyno.2004.11.031","article-title":"Role of laparoscopy to assess the chance of optimal cytoreductive surgery in advanced ovarian cancer: a pilot study","volume":"96","author":"Fagotti","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.gofs.2018.12.013_bib0780","doi-asserted-by":"crossref","first-page":"642e1","DOI":"10.1016\/j.ajog.2008.06.052","article-title":"Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma","volume":"199","author":"Fagotti","year":"2008","journal-title":"Am J Obstet Gynecol"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.gofs.2018.12.013_bib0785","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1525-1438.2007.01098.x","article-title":"Timing of debulking surgery in advanced ovarian cancer","volume":"18","author":"Vergote","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.gofs.2018.12.013_bib0790","first-page":"CD009786","article-title":"Laparoscopy for diagnosing resectability of disease in patients with advanced ovarian cancer","author":"Rutten","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.gofs.2018.12.013_bib0795","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1200\/JCO.2016.69.2962","article-title":"Laparoscopy to predict the result of primary cytoreductive surgery in patients with advanced ovarian cancer: a randomized controlled trial","volume":"35","author":"Rutten","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gofs.2018.12.013_bib0800","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ygyno.2008.04.042","article-title":"External validation of a laparoscopic-based score to evaluate resectability of advanced ovarian cancers: clues for a simplified score","volume":"110","author":"Brun","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.gofs.2018.12.013_bib0805","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ygyno.2015.07.095","article-title":"Definition of a dynamic laparoscopic model for the prediction of incomplete cytoreduction in advanced epithelial ovarian cancer: proof of a concept","volume":"139","author":"Petrillo","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.gofs.2018.12.013_bib0810","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jmig.2007.02.008","article-title":"Laparoscopic treatment of deep endometriosis with segmental colorectal resection: short-term morbidity","volume":"14","author":"Mereu","year":"2007","journal-title":"J Minim Invasive Gynecol"},{"key":"10.1016\/j.gofs.2018.12.013_bib0815","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ygyno.2009.09.015","article-title":"Should laparoscopy be included in the work-up of advanced ovarian cancer patients attempting interval debulking surgery?","volume":"116","author":"Fagotti","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.gofs.2018.12.013_bib0820","first-page":"4469","article-title":"External validation of a laparoscopic-based score to evaluate resectability for patients with advanced ovarian cancer undergoing interval debulking surgery","volume":"31","author":"Chereau","year":"2011","journal-title":"Anticancer Res"},{"key":"10.1016\/j.gofs.2018.12.013_bib0825","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.ejso.2013.03.022","article-title":"Diagnostic accuracy of hand-assisted laparoscopy in predicting resectability of peritoneal carcinomatosis from gynecological malignancies","volume":"39","author":"Varnoux","year":"2013","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.gofs.2018.12.013_bib0830","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ygyno.2005.09.060","article-title":"Diagnostic open laparoscopy in the management of advanced ovarian cancer","volume":"100","author":"Angioli","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.gofs.2018.12.013_bib0835","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1053\/ejso.2002.1380","article-title":"Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer","volume":"29","author":"Tentes","year":"2003","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.gofs.2018.12.013_bib0840","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ejso.2017.11.003","article-title":"Prognostic value of peritoneal cancer index in primary advanced ovarian cancer","volume":"44","author":"Llueca","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.gofs.2018.12.013_bib0845","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ygyno.2010.09.010","article-title":"Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment","volume":"120","author":"Aletti","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.gofs.2018.12.013_bib0850","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.18632\/oncotarget.14100","article-title":"A novel nomogram based on LODDS to predict the prognosis of epithelial ovarian cancer","volume":"8","author":"Xu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.gofs.2018.12.013_bib0855","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.ygyno.2014.01.036","article-title":"A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy","volume":"132","author":"Previs","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.gofs.2018.12.013_bib0860","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ygyno.2011.12.423","article-title":"Nomogram for predicting 5-year disease-specific mortality after primary surgery for epithelial ovarian cancer","volume":"125","author":"Barlin","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.gofs.2018.12.013_bib0865","first-page":"4043","article-title":"Nomogram for suboptimal cytoreduction at primary surgery for advanced stage ovarian cancer","volume":"31","author":"Gerestein","year":"2011","journal-title":"Anticancer Res"},{"key":"10.1016\/j.gofs.2018.12.013_bib0870","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ygyno.2007.09.020","article-title":"Nomogram for survival after primary surgery for bulky stage IIIC ovarian carcinoma","volume":"108","author":"Chi","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.gofs.2018.12.013_bib0875","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1200\/JCO.2007.11.0114","article-title":"PIEPOC: a new prognostic index for advanced epithelial ovarian cancer\u00a0\u2014\u00a0Japan Multinational Trial Organization OC01-01","volume":"25","author":"Teramukai","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gofs.2018.12.013_bib0880","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1054\/bjoc.2001.2030","article-title":"A prognostic model for ovarian cancer","volume":"85","author":"Clark","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.gofs.2018.12.013_bib0885","doi-asserted-by":"crossref","first-page":"e0187245","DOI":"10.1371\/journal.pone.0187245","article-title":"A pre-operative predictive score to evaluate the feasibility of complete cytoreductive surgery in patients with epithelial ovarian cancer","volume":"12","author":"Chesnais","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.gofs.2018.12.013_bib0890","doi-asserted-by":"crossref","first-page":"635","DOI":"10.4143\/crt.2016.282","article-title":"Nomograms predicting platinum sensitivity, progression-free survival, and overall survival using pretreatment complete blood cell counts in epithelial ovarian cancer","volume":"49","author":"Paik","year":"2017","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.gofs.2018.12.013_bib0895","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ygyno.2014.11.004","article-title":"Nomogram for predicting incomplete cytoreduction in advanced ovarian cancer patients","volume":"136","author":"Shim","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.gofs.2018.12.013_bib0900","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ygyno.2014.07.002","article-title":"A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125\u00a0to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer","volume":"134","author":"Suidan","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.gofs.2018.12.013_bib0905","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000113051","article-title":"Preoperative predictors for residual tumor after surgery in patients with ovarian carcinoma","volume":"72","author":"de Jong","year":"2007","journal-title":"Oncology"},{"key":"10.1016\/j.gofs.2018.12.013_bib0910","first-page":"63","article-title":"Nomogram for 30-day morbidity after primary cytoreductive surgery for advanced stage ovarian cancer","volume":"37","author":"Nieuwenhuyzen-de Boer","year":"2016","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1016\/j.gofs.2018.12.013_bib0915","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2015.10.025","article-title":"Risk-prediction model of severe postoperative complications after primary debulking surgery for advanced ovarian cancer","volume":"140","author":"Kumar","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.gofs.2018.12.013_bib0920","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejca.2009.10.017","article-title":"Prediction of 30-day morbidity after primary cytoreductive surgery for advanced stage ovarian cancer","volume":"46","author":"Gerestein","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.gofs.2018.12.013_bib0925","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ygyno.2015.11.022","article-title":"Prediction of incomplete primary debulking surgery in patients with advanced ovarian cancer: an external validation study of three models using computed tomography","volume":"140","author":"Rutten","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.gofs.2018.12.013_bib0465","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/bjc.2013.717","article-title":"External validation of three prognostic models for overall survival in patients with advanced-stage epithelial ovarian cancer","volume":"110","author":"van de Laar","year":"2014","journal-title":"Br J Cancer"}],"container-title":["Gyn\u00e9cologie Obst\u00e9trique Fertilit\u00e9 &amp; S\u00e9nologie\u00a0"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468718918303817?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468718918303817?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:38:40Z","timestamp":1762853920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468718918303817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":93,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S2468718918303817"],"URL":"https:\/\/doi.org\/10.1016\/j.gofs.2018.12.013","relation":{},"ISSN":["2468-7189"],"issn-type":[{"value":"2468-7189","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pertinence des marqueurs tumoraux, scores (cliniques et biologiques) et algorithmes \u00e0 vis\u00e9e diagnostique et pronostique devant une masse ovarienne suspecte d\u2019un cancer \u00e9pith\u00e9lial. Article r\u00e9dig\u00e9 sur la base de la recommandation nationale de bonnes pratiques cliniques en canc\u00e9rologie intitul\u00e9e \u00ab\u00a0Conduites \u00e0 tenir initiales devant des patientes atteintes d\u2019un cancer \u00e9pith\u00e9lial de l\u2019ovaire\u00a0\u00bb \u00e9labor\u00e9e par FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY sous l\u2019\u00e9gide du CNGOF et labellis\u00e9e par l\u2019INCa","name":"articletitle","label":"Article Title"},{"value":"Gyn\u00e9cologie Obst\u00e9trique Fertilit\u00e9 & S\u00e9nologie\u00a0","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gofs.2018.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}